HC Wainwright & Co. Reiterates Buy on PDS Biotechnology, Maintains $7 Price Target

PDS Biotechnology Corp.

PDS Biotechnology Corp.

PDSB

0.00

HC Wainwright & Co. analyst Joseph Pantginis reiterates PDS Biotechnology (NASDAQ: PDSB) with a Buy and maintains $7 price target.